Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

3H-1,2-dithiole-3-thione as a novel therapeutic agent for the treatment of experimental autoimmune encephalomyelitis.
Phase-Sensitive Inversion-Recovery MRI Improves Longitudinal Cortical Lesion Detection in Progressive MS.
Cryptococcal meningitis in a multiple sclerosis patient taking natalizumab.
Symptom overlap in anxiety and multiple sclerosis.
Fatal Neuroinflammation in a Case of Multiple Sclerosis with Anti-Natalizumab Antibodies.
Adherence to interferon β-1a therapy using an electronic self-injector in multiple sclerosis: a multicentre, single-arm, observational, phase IV study.
Partnering to increase access to community exercise programs for people with stroke, acquired brain injury, and multiple sclerosis.
Prospective Examination of Anxiety and Depression Before and During Confirmed and Pseudoexacerbations in Patients With Multiple Sclerosis.
Laquinimod Halted MS Disability But Not Relapses
Cognitive impairment as unusual first manifestation in late-onset relapsing-remitting multiple sclerosis.
Epistasis and immunity: the role of genetic interactions in autoimmune diseases.
The cytokines cardiotrophin-like cytokine/cytokine-like factor-1 (CLC/CLF) and ciliary neurotrophic factor (CNTF) differ in their receptor specificities.
Naltrexone
[Multiple sclerosis: new approaches to comprehensive treatment and rehabilitation using the method of reflexology].
Multiple sclerosis disease-modifying therapy prescribing patterns in ontario.
No Regional Gray Matter Atrophy Differences between Pediatric- and Adult-Onset Relapsing-Remitting Multiple Sclerosis.
Magnetic Resonance Phase Alterations in Multiple Sclerosis Patients with Short and Long Disease Duration.
Association of IL4 and IL4R polymorphisms with multiple sclerosis susceptibility in Caucasian population: A meta-analysis.
Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy.
The effect of vitamin a supplementation on disease progression, cytokine levels and gene expression in multiple sclerotic patients: study protocol for a randomized controlled trial.
Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial.
Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis.
Neuronal antigens recognized by cerebrospinal fluid IgM in multiple sclerosis.
Association between apolipoprotein E gene polymorphism and the risk of multiple sclerosis: A meta-analysis of 6977 subjects.
Novartis updates US label on Gilenya® following discussions with the FDA

Pages